Results 61 to 70 of about 32,890 (266)

Building a Framework for Sexual and Reproductive Healthcare in the Rheumatology Context: Content and Approaches

Arthritis Care &Research, Accepted Article.
People with systemic autoimmune and rheumatic diseases (SARDs) are at higher risk than the general population of experiencing adverse pregnancy and perinatal outcomes such as preeclampsia, intrauterine growth restriction, and maternal and/or fetal death.
Mehret Birru Talabi, Sonya Borrero
wiley   +1 more source

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation [PDF]

, 2017
Background: Psoriasis is a chronic inflammatory disease that predominantly affects the skin. Adalimumab (HUMIRA®, AbbVie, Maidenhead, UK), etanercept (Enbrel®, Pfizer, New York, NY, USA) and ustekinumab (STELARA®, Janssen Biotech, Inc., Titusville, NJ ...
AbbVie, Ali, All Wales Medicines Strategy Group, All Wales Therapeutics and Toxicology Centre, Altmeyer, Amgen Inc, Amgen Inc, Amgen Inc, Amgen Inc, Amornpinyokeit, Asahina, Balzola, Barker, Basko-Plluska, Basra, Benoit, Berth-Jones, Bigby, Bissonnette, Bonafede, Brunasso, Brănişteanu, Burden-Teh, Burden-Teh, Burden-Teh, Burmester, Burmester, Centre for Reviews and Dissemination, Chaudhari, Chen, Chingcuanco, Chiu, Christiansen, Christophers, Cooper, Corbett, da Silva, Dakin, de Jager, De Jager, de Jager, Department of Health, Dias, Dias, Dias, Dias, DiMarco, Dixon, Dolan, Driessen, Eissing, Elder, Elewski, Esposito, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, EuroQol Research Foundation, Faerber, Fallah Arani, Famenini, Farhi, Feldman, Flytström, Fonia, Garber, Geiger, Gisondi, Gniadecki, Gniadecki, Gordon, Gordon, Gottlieb, Gottlieb, Greater Medicines Management Group, Griffiths, Guenther, Heydendael, Heydendael, Higgins, Higgins, Ho, Holme, Howe, Ibfelt, Ibrahim, Igarashi, Italian Multicenter Study Group on Cyclosporin in Psoriasis, Janagond, Jankovic, Janssen Biotech, Inc, Janssen Research & Development, LLC, Janssen Research & Development, LLC, Janssen Research & Development, LLC, Janssen-Cilag International, Joint Formulary Committee, Khan, Kim, Kim, Kimball, Klufas, Koo, Kragballe, Krueger, Krueger, Kurd, Laburte, Landells, Landells, Landells, Langley, Langley, Langley, Langley, Lara-Corrales, Lebwohl, Lebwohl, Lefebvre, Lefebvre, Leman, Leonardi, Leonardi, Levy, Lewis-Jones, Lu, Lynde, López-Ferrer, Mahé, Meffert, Melis, Menter, Menter, Menter, MIMS, Moher, National Horizon Scanning Centre, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, NIHR Horizon Scanning Centre, NIHR Horizon Scanning Centre, Norman, Novartis Pharmaceuticals, Novartis Pharmaceuticals, Office for National Statistics, Oostveen, Paller, Paller, Paller, Paller, Paller, Paller, Paller, Paller, Paller, Papp, Papp, Papp, Papp, Papp, Papp, Papp, Papp, Papp, Parisi, Park, Paul, Pereira, Pfizer, Pfizer, Phillipp, Puig, Ranjan, Reich, Reich, Rencz, Revicki, Richardson, Rodgers, Romero-Maté, Royal College of Paediatrics and Child Health, Ruano, Ruzicka, Ryan, Salek, Sanclemente, Saurat, Schabert, Seminara, Seyger, Shah, Siegfried, Siegfried, Signorovitch, Smith, Soliman, Strand, Strohal, Strohal, Sutton, Takashima, Tanew, Tarp, Torii, Tsai, Umezawa, Upton, US Food and Drug Administration, van de Kerkhof, van Reenen, Varni, Varni, Varni, Vencovsky, Vickers, Warren, Warren, Woods, Woolacott, Wu, Wyeth, Yang, Young, Zachariae, Zhu   +239 more
core   +3 more sources

Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study

Dermatologic Therapy, 2023
Introduction Bimekizumab treatment resulted in improved clinical outcomes in patients with moderate-to-severe plaque psoriasis in BE VIVID, a 52-week, phase 3, randomized, ustekinumab and placebo-controlled study.
A. Asahina, Y. Okubo, A. Morita, Y. Tada, A. Igarashi, R. Langley, D. Deherder, Mizuho Matano, V. Vanvoorden, Maggie Wang, M. Ohtsuki, H. Nakagawa   +11 more
semanticscholar   +1 more source

Integrating Human Intestinal Organoids into FDA'S New Approach Methodologies for Drug Discovery

Advanced Science, EarlyView.
Illustration summarizes how human intestinal organoids (HIOs) are becoming transformative in preclinical research. Preclinical drug discovery pipelines often rely on animal models for ADMET studies, even though interspecies ADME gaps, poor external validity, and high attrition rates are common.
Debarun Patra, Ibrahim M. Sayed, Souhrid Mukherjee, Honit Piplani, Aida Habtezion, Michael J. Rosen, Jospeh C. Wu   +6 more
wiley   +1 more source

Treatment efficacy and patient satisfaction of ustekinumab compared with tumor necrosis factor-alpha inhibitors in Chinese patients with moderate-to-severe psoriasis: a real-world study

Journal of Dermatological Treatment
Background Ustekinumab is an interleukin (IL)-12/IL-23 inhibitor for the treatment of moderate-to-severe psoriasis.Objective This real-world study compared ustekinumab and tumor necrosis factor-alpha inhibitors (TNFis) in Chinese moderate-to-severe ...
Bin Guo, Xiaobo Jin, Leiqiang Fan, Yanfeng Zhang, Bing Xu, Tao Yang   +5 more
doaj   +1 more source

Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature [PDF]

, 2015
Background: Inteleukin (IL)12 and IL23 are two main cytokines involved in the pathogenesis of immune-mediated disease. IL12 is produced by macrophages and B lymphocytes and mediates differentiation of Th1 lymphocytes, while IL23 is a pro-inflammatory ...
Chimenti, MS, Galluzzo, M, Novelli, L, Perricone, R, Talamonti, M, Teoli, M, Triggianese, P   +6 more
core   +1 more source

Infant ustekinumab Clearance, Risk of Infection, and Development after exposure during pregnancy.

Clinical Gastroenterology and Hepatology
BACKGROUND AND AIM Evidence on ustekinumab safety in pregnancy is gradually expanding, but its clearance in the postnatal period is unknown. The aim of this study was to investigate ustekinumab concentrations in umbilical cord blood and rates of ...
M. Julsgaard, J. Wieringa, S. M. Baunwall, B. Bibby, Gertjan J. A. Driessen, L. Kievit, J. Brodersen, Anja Poulsen, J. Kjeldsen, M. M. Hansen, Hai Q Tang, C. Balmer, H. Glerup, J. Seidelin, K. Haderslev, L. Svenningsen, S. Wildt, Mie A. Juel, A. Neumann, Jens Fuglsang, T. Jess, Anne-Mette Hasse, C. Hvas, J. Kelsen, C. Janneke van der Woude   +24 more
semanticscholar   +1 more source

Effectiveness, safety and quality‐of‐life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non‐interventional, prospective, German multicentre PERSIST study

Journal of the European Academy of Dermatology and Venereology, 2023
PERSIST was a prospective, non‐interventional, real‐world study of guselkumab and ustekinumab in adult patients with moderate‐to‐severe plaque psoriasis in Germany.
S. Gerdes, M. Hoffmann, K. Asadullah, B. Korge, D. Mortazawi, N. Krüger, Y. Personke, S. Tabori, M. Gomez, S. Wegner, F. Kreimendahl, F. Taut, M. Sticherling, Janssen-Cilag GmbH   +13 more
semanticscholar   +1 more source

Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Risankizumab is a high‐cost biologic treatment for chronic plaque psoriasis, an immune‐mediated inflammatory disease presenting with painful red scaly skin lesions. Inter‐individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (
Charlotte M. Thomas, Jessica Ruoheng Wei, David Baudry, Zehra Arkir, Bola Coker, Tejus Dasandi, Kingsley Powell, Monica Arenas‐Hernandez, Jenny Leung, Krystal Rawstron, Chioma Nwaogu, Richard Woolf, Andrew E. Pink, Jonathan Barker, Joseph F. Standing, Catherine H. Smith, Satveer K. Mahil   +16 more
wiley   +1 more source

AVT04, a Biosimilar to Reference Product Ustekinumab, for the Treatment of Plaque Psoriasis: Insights from a Real-World Experience up to 28 Weeks

Dermatology and Therapy
Introduction This study aims to evaluate the real-life efficacy and safety of a biosimilar to reference product (RP) ustekinumab for the treatment of plaque psoriasis in different patient scenarios.
Edoardo Mortato, Marina Talamonti, Lorenzo Savastano, Lorenzo Marcelli, Lorenzo Tofani, Valerio Gneo, Domenico Marrapodi, Maria Rosa Ingrosso, Luca Bianchi, Marco Galluzzo   +9 more
doaj   +1 more source